Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.

[powerpress]

Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.

[powerpress]

Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.

[powerpress]

Dr. Heather Wakelee, from Stanford University, describes which molecular markers she seeks for NSCLC patients.

[powerpress]

Dr. Karen Kelly, of the University of California, Davis, gives her view on more widespread availability of new mutation tests.

[powerpress]

Drs. Ross Camidge and Corey Langer describe their practice when patients with advanced NSCLC bring them the results of broad molecular marker testing.

[powerpress]

Dr. Greg Riely, from Memorial Sloan-Kettering, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for patients with squamous and other lung cancer subtypes.

[powerpress]

Dr. Sarah Goldberg from Yale Cancer Center describes which patients with advanced NSCLC she seeks molecular marker testing on.

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, gives his view on more widespread availability of new mutation tests.

[powerpress]